Alexion Announces CFO Succession

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans for the transition of Executive Vice President and Chief Financial Officer Paul Clancy later this year. He will be succeeded by Aradhana Sarin, M.D., who is currently the Chief Strategy and Business Officer. Mr. Clancy and Dr. Sarin will work together in a formal transition that will occur after the filing of the company’s third quarter results, and Mr. Clancy will remain at Alexion and continue to serve as a senior advisor through the middle of 2020.

“On behalf of the entire Board and executive team, I would like to thank Paul for his enormous contributions and leadership during such a critical time for the company. Over the last two years, he has played an invaluable role in our efforts to rebuild Alexion, refocus our corporate strategy and position the company for its next chapter,” said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion. “As Paul’s successor, I am confident Aradhana will help us continue to build on the strong foundation we’ve established and execute on our business strategies. In her nearly two years at Alexion, Aradhana has created significant value for the company, leading our business development efforts to rebuild our pipeline and driving our strategic vision as we position the company for long-term success.”

Dr. Sarin has been with Alexion since November 2017, during which time she has taken on roles of increasing responsibility. She is currently a member of Alexion’s executive committee, serving as Executive Vice President, Chief Strategy and Business Officer, and was previously Senior Vice President, Business Development and Corporate Strategy. Trained as a medical doctor in India, Dr. Sarin had more than 20 years of experience at global financial institutions prior to joining Alexion with extensive knowledge of global healthcare systems as well as an excellent understanding of the biopharmaceutical sector. In her time at Alexion, Dr. Sarin has been responsible for ensuring continued growth and executional excellence across the company’s increasingly complex and diverse portfolio. During the past two years, she led the company’s disciplined business development efforts, overseeing nine business development deals that have been critical to rebuilding and diversifying Alexion’s pipeline. She has also been responsible for ensuring the company is positioned to meet the demands of its refocused corporate strategy.

“With the experienced team and resources we have in place, Alexion is well positioned to continue executing on our mission of transforming the lives of people with rare diseases,” said Dr. Sarin. “I look forward to continuing to work with our executive team and our Board to deliver on our promising future.”

“It has been a true honor to serve as the CFO of Alexion during this time of significant transformation,” said Mr. Clancy. “I am extremely proud of the Alexion team, the progress we have made and our many accomplishments aimed at improving the lives of people with rare diseases. I believe Alexion has great potential and the ability to achieve its strategic vision, and I will work with the entire team to ensure a seamless transition.” – Business Wire